Hillstream Biopharma

Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. It also develops the Trident Artificial Intelligence (TAI) precision medicine platform which is used to identify biomarkers in its clinical programs to target a specific patient segment. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

Earnings data Q1 2023

Earnings data Q2 2023

BRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, will be attending the 35th Annual ROTH Conference, being held March 12–14 at The Ritz-Carlton Hotel in Dana Point, California.

Hillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023

Company Hosted its R&D Day to Discuss Product and Pipeline Goals Across 4 Pipeline Candidates and its Quatramer™ Tumor-Targeting Platform; Multiple inflection points over the next 12-18 Months

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Company's Novel Emerging Anti-Cancer Mechanism, Ferroptosis, Addresses Potential Key Target Oncology Markets Projected to reach $11 Billion in 2028

Hillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ET

HER2 and HER3 Conformational Domain Bridging Epitopes in Antibodies via an Exclusive Option Allows Hillstream BioPharma to Develop Proprietary Multi-format Biologics (bispecific, ADC, CAR-T) against Drug Resistant Breast and Gastric Cancers

Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer

Biosig Technologies Inc

Vallon Pharmaceuticals

Why investing in penny stocks in the long term could be the right choice The post The Benefits of Investing in Penny Stocks in the Long Term  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The Benefits of Investing in Penny Stocks in the Long Term

Synergy and crosstalk between Ferroptosis and the Anti-PD-1 Pathways in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells

In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer

Preclinical Update on HSB-510 and navitoclax, a Novel Quatramer™-based, First-in-Class Dual Inhibitor of PI3-Kδ / HDAC6 in combination with navitoclax (BCL-XL/BCL-2 inhibitor)

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias

Quatramer-based HSB-1216 combined with anti-MUC1-C antibody designed to target cancer stem cells (CSCs) by inducing ferroptosis in drug resistant cancers

Hillstream BioPharma to Host Virtual R&D Day to Showcase its Emerging Immuno-oncology Pipeline Targeting Drug-Resistant Cancers

It's not every day that you hear about Hillstream BioPharma (NASDAQ: HILS ) in the financial headlines. Today, however, HILS stock is skyrocketing more than 100% on heavy trading volume.

Why Is Hillstream BioPharma (HILS) Stock Up 100% Today?

Context Therapeutics LLC

Intelligent Bio Solutions Inc

Rent the Runway

Silo Pharma Inc

Sonoma Pharmaceuticals

Spectrum Pharma

Penny Stocks With News Light Up The Scanners This Week This week

7 Top Penny Stocks To Watch With Big News This Week

Development expected to capitalize upon tumor targeting Quatramers™

Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers

BRIDGEWATER, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the Virtual Sidoti Micro-Cap Conference being held on January 18-19, 2023.

Hillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023

Akebia Therapeutics

Bone Biologics Corp

HTG Molecular Diagnostics

Kalera PLC

Pagaya Technologies Ltd

SINTX Technologies Inc

Sio Gene Therapies

Venator Materials

Wearable Devices Ltd

Penny stocks to watch trading under $1 right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 10 Stocks Under $1 To Watch

Low float penny stocks under $1 to watch after AMAM stock explodes over 500%. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 3 Low Float Stocks Under $1 To Watch

Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb's Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets

BRIDGEWATER, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the 2022 RHK Capital Disruptive Growth Conference hosted at Reed Smith in New York City on December 5-6, 2022.

Hillstream BioPharma to Present at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

Abstract highlights data from HSB-1216 in acute myeloid leukemia (AML) growth Abstract highlights data from HSB-1216 in acute myeloid leukemia (AML) growth

Hillstream's New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR Symposium

BRIDGEWATER, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, today announced that Randy Milby, Founder and Chief Executive Officer will present in-person and host one-on-one meetings with investors at the following conferences:

Hillstream BioPharma, Inc. to Present at Upcoming Investor Conferences

BRIDGEWATER, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, will participate in the Fierce Biotech Summit, being held at The Westin Copley Place in Boston, on September 19-20, 2022.

Hillstream BioPharma to Participate in the Fierce Biotech Summit on September 19-20

BRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will attend the 12th Annual World Orphan Drug Congress USA 2022, being held at the Hynes Convention Center in Boston, on July 11-13, 2022.

Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13

Acutus Medical

Agile Therapeutics

Cybin

Evofem Biosciences

Penny stocks to watch with news The post Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving

Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint Inhibitors Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint Inhibitors

Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments

Hillstream BioPharma Inc (NASDAQ: HILS) shares are trading higher after it authorized a share repurchase program to acquire up to $1 million in common stock.  As of March 31, Hillstream had approximately $11.1 million in cash and 11.4 million shares of common stock.

Why Hillstream BioPharma Shares Are Trading Higher Today?

HILS stock explodes on Monday & here's why. The post Penny Stocks To Watch: Why Hillstream BioPharma (HILS) Is Moving Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why Hillstream BioPharma (HILS) Is Moving Today

BRIDGEWATER, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream,” the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, today provided a corporate update for its investors and a roadmap of clinical studies through 2023.

News for Hillstream Biopharma Stock (HILS)